Assessing the predictive value of smoking history for immunotherapy outcomes in bladder cancer patients
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Smoking history may predict response to immune checkpoint inhibitors in bladder cancer. Former smokers showed a trend towards better outcomes and higher PD-L1 expression, suggesting its role in personalized treatment.
Area Of Science
- Oncology
- Immunotherapy
- Bladder Cancer Research
Background
- Immune checkpoint inhibitors (ICIs) show variable effectiveness in bladder cancer.
- Predicting patient response to ICIs is critical for treatment optimization.
Purpose Of The Study
- To investigate the correlation between smoking history and outcomes in bladder cancer patients treated with ICIs.
- To explore the association between smoking status, PD-L1 expression, and immunotherapy response.
Main Methods
- Retrospective analysis of 348 bladder cancer patients receiving ICIs.
- Validation using PD-L1 immunohistochemical staining data from 248 patients.
- Multivariate logistic and Cox proportional hazard regressions were employed.
Main Results
- No statistically significant difference in overall survival across smoking statuses.
- A trend towards better immunotherapy response was observed in former smokers.
- Former smokers exhibited significantly higher PD-L1 expression compared to current and never smokers.
Conclusions
- Smoking history is a potential predictor of immunotherapy response in bladder cancer.
- Findings support the integration of smoking history into personalized treatment strategies.
- Further research into lifestyle factors influencing treatment outcomes is warranted.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
